BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29557343)

  • 1. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
    Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
    Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
    Aminkeng F; Bhavsar AP; Visscher H; Rassekh SR; Li Y; Lee JW; Brunham LR; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Amstutz U; Rieder MJ; Bernstein D; Carleton BC; Hayden MR; Ross CJ;
    Nat Genet; 2015 Sep; 47(9):1079-84. PubMed ID: 26237429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
    Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
    Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
    Siemens A; Rassekh SR; Ross CJD; Carleton BC
    Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
    Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
    Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
    Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
    Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
    Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
    J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.
    Wang X; Sun CL; Quiñones-Lombraña A; Singh P; Landier W; Hageman L; Mather M; Rotter JI; Taylor KD; Chen YD; Armenian SH; Winick N; Ginsberg JP; Neglia JP; Oeffinger KC; Castellino SM; Dreyer ZE; Hudson MM; Robison LL; Blanco JG; Bhatia S
    J Clin Oncol; 2016 Mar; 34(8):863-70. PubMed ID: 26811534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
    Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
    Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
    Chang VY; Wang JJ
    Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
    Agunbiade TA; Zaghlol RY; Barac A
    Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
    Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
    Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Leong SL; Chaiyakunapruk N; Lee SW
    Sci Rep; 2017 Feb; 7(1):39. PubMed ID: 28232737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
    Schneider BP; Shen F; Gardner L; Radovich M; Li L; Miller KD; Jiang G; Lai D; O'Neill A; Sparano JA; Davidson NE; Cameron D; Gradus-Pizlo I; Mastouri RA; Suter TM; Foroud T; Sledge GW
    Clin Cancer Res; 2017 Jan; 23(1):43-51. PubMed ID: 27993963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.